Description: This session will discuss the implications of a proposed federal catastrophic long-term care program, the WISH Act. The session will focus on the benefit to consumers, the financial soundness of the proposed program and the regulatory steps necessary to achieve the desired public/private insurance program goals. The session may also consider state based reform proposals.

Description: Article on the history of the Long Term Care Discussion Group, a Washington DC-based venue for discussing long-term care and related issues for over 20 years.

Description: A Chief Actuary’s responsibilities in managing an LTC block require a strong understanding of the past and the ability to use that and emerging trends and challenges to prognosticate the future. During this session a panel of Chief Actuaries will share their thoughts about the current and future states of the LTC industry and how they are tackling their top challenges, such as COVID, LDTI implementation, regulatory changes, and their work force.

Description: The National Academy of Social Insurance (the Academy) recently released a comprehensive study on models for states interested in pursuing social insurance initiatives for LTSS, paid leave and child care reform. The report explores strategies that states could pursue to better support families in meeting evolving care needs over the lifespan. Actuarial projections for illustrative policy options are included. The presenters will report back the Academy study panel's findings, provide in-depth insights into Washington State's new long-term care social insurance program, and briefly report on other state activity in the LTSS and paid leave domains.

Description: There are three parts to this article: 1. An overview of the demographics and method of supply of LTC 2. A review of the ongoing debate on the role of public funding, and 3. A summary of the insurance industry’s response

Description: We explore copay accumulators, copay maximizers, and various programs available in the commercial market. We discuss health plan, member, PBM, and pharmaceutical manufacturer implications, in the commercial market itself and other markets.